A semiquantitative estimation of human T-lymphotropic virus type I (HTLV-I) integration by peripheral blood mononuclear cells (PBMC) was performed. Genomic DNA samples derived from 134 HTLV-I carriers were subjected to 40 or 60 cycles of the polymerase chain reaction to amplify the pol region of HTLV-I. The HTLV-I genome was detected by dot hybridization using a UP-labeled oligonucleotide probe for the pol region. The radioactivity of hybridized dot membranes was then counted with an RI Imaging System (Ambis Inc, San Diego, CA) and the HTLV-I genome dose was determined by comparison with standard curve for serially diluted HTLV-I genome-positive DNA. A wide range of variation of HTLV-I genome integration was observed. When the
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0 1991 by The American Society of Hematology. 0006-4971 191 ~7808-0005$3.00/0 integrated genome dose was calculated as the number of HTLV-I copies per 100 PBMC, 7 carriers (5%) had more than 10 copies, 56 (42%) had 1 to 10 copies, 46 (34%) had 0.1 to 1 copy, and 24 (18%) had less than 0.1 copy. In one sample, the HTLV-I genome was undetectable, which may indicate that the integrated genome was present at less than 0.01 copies per 100 PBMC. Age-or sex-related variations in the distribution of individuals with different HTLV-I genome were rather limited. However, carriers with a high level of the HTLV-I genome were always more than 30 years old and were predominantly male (six of seven).
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individual. Recently, the polymerase chain reaction (PCR) has been applied for detecting HTLV-I genomes?-" Although this technology enables us to detect the viral integration with extremely high sensitivity, quantitative measurement of the viral genome dose has remained difficult.
In this study, we semiquantitatively examined HTLV-I genome dose in the PBMC of asymptomatic HTLV-I carriers by means of the PCR and the RI Imaging System (Ambis Inc, San Diego, CA). A more than 103-fold variation in the viral genome dose was found among the HTLV-I carriers. The association of the viral genome dose with age was also examined.
MATERIALS AND METHODS
One hundred thirty-four asymptomatic HTLV-I carriers in Nagasaki, one of the endemic areas for HTLV-I infection in Japan, were examined (Table 1) . HTLV-I carrier status was determined by the presence of anti-HTLV-I antibodies detected by the gelatin particle agglutination test (Serodia-ATLA, Fujirebio, Tokyo, Japan), enzyme-linked immunosorbent assay (Eitest-ATL; Eisai Co, Tokyo, Japan), or indirect immunofluorescence with HTLV-I' cells as the targets. Twenty-two patients with HAM/TSP and 23 healthy seronegatives (noncarriers) were also analyzed. Three HTLV-I+ cell lines (MT-2," HUT-102,' and ATKS) and fresh ATL cells were used as positive controls, whereas three HTLV-I-cell lines (HUT-78," HL-60,14 and HLCL-1) were used as the negative controls.
High molecular weight cellular DNA was extracted as described previously" from PBMC prepared by the Ficoll-Hypaque gradient method (Nyegaard, Oslo, Norway).
DNA amplification in vitro was performed by the protocol of Saiki et with some modificati~n.'~.'~ Sequences of oligonucleotide primers and detecting probes are shown in Table 2 . The reaction mixture contained 0.5 kg of chromosomal DNA, 0.3 kg of each primer, 800 kmol/L of dNTPs (mixture of dATP, dCTP, dGTP, and d'ITP) , 16.6 mmol1L (NH,),SO,, 67 mmol/L Tris-HC1 (pH 8.8), 6.7 mmol/L MgCI,, 10 mmol/L 2-mercaptoethanol, 100 pg/mL of gelatin, and 1 U of Taq DNA polymerase (Perkin Elmer Cetus, Nonvalk, CT) in a total volume of 50 kL. Samples underwent 40 cycles of heating to 95°C for 60 seconds to denature the DNA, cooling to 55°C for 90 seconds for annealing of primers, and incubation at 72°C for 90 seconds for primer extension by an automated heat block (Program Temp Control System PC 500 Astec Inc, Fukuoka, Japan). Samples in which HTLV-I genomes Blood donors. were undetectable after 40 cycles of amplification were reanalyzed after another 20 cycles of the PCR were performed with the addition of 0.5 U of Taq DNA polymerase. Test samples were run in parallel with standard positive (mentioned later) and negative samples in each experiment. Aliquots (10 pL) of the reaction products were spotted onto nylon filters. The filters were dried and prehybridized for 3 to 6 hours at 56°C in 3 mol/L tetramethylammonium chloride, 50 mmol/L Tris-HC1 (pH 8.0), 2 mmol/L EDTA, 100 pg/mL of denatured salmon sperm DNA, 0.1% sodium dodecyl sulfate (SDS), and 5X Denhardt's solution. Then filters were hybridized for 1 hour at 46°C in the same mixture containing a 3zP-endlabeled oligoprobe. Filters were washed twice in 2X SSC (1X SSC: 150 mmol/L sodium chloride, 15 mmol/L sodium citrate) with 0.1% SDS for 5 minutes at room temperature, then stringently washed twice in 5X SSC with 0.1% SDS for 15 minutes at 50°C. Subsequently, filters were washed twice in the hybridization buffer without Denhardt's solution and salmon sperm DNA at 57.5"C for 1 hour. The filters were then exposed to Kodak XAR-5 film (Eastman Kodak, Rochester, NY) at -70°C for 15 to 24 hours using an intensifying screen.
PCR.
After dot hybridization, the radioactivity of each dot was counted for 5 to 8 hours using the RI Imaging System. The RI Imaging System images and quantitates with a degree of sensitivity equal to the combined use of autoradiography and scintillation counting. The detector is an enhanced multiwire proportional counter. An array of radiation detectors is created by 34 anode wires and 28 cathode strips that intersect at right angles to form 952 detectors. It detects radioactivity directly from samples without destruction of the sample membrane. The filter membrane analyzed by the RI Imaging System was also processed for standard autoradiography, as described previously.
Dot hybridization.
Analysis by the RI Imaging System. Standard samples. For quantitative analysis of the HTLV-I genome levels in PBMC, standard samples were prepared by diluting DNA from an ATL-derived cell line (ATKS), which has normal diploid 46XY chromosomes and one copy of the HTLV-I genome per cell. Tenfold serial dilutions (from 100% to 0.001%) of HTLV-I-positive cellular DNA, with a constant total DNA content, were prepared by dilution with DNA from HTLV-I-PBMC.
As an internal control for the PCR, c-hi'-ras amplification was also examined in all samples, using the following primers and oligonucleotide probe: primer A (5'-GACTGAATATAAACTTGTGG-3'), primer B (5'-CTATTGT-TGGATCATATTCG-3'), and a '*P-labeled oligoprobe (5'-GTTGGAGCTGGTGGCGTAGG-3'). Twenty-five cycles of the PCR were performed. After dot hybridization, each sample was analyzed by the RI Imaging System. DNA samples were digested completely with Pst I restriction enzyme, separated on agarose gel, and transferred to a nitrocellulose filter. Hybridization was performed at 42°C with 1 X lo7 cpm/mL of 32P-labeled probe (P255M-07 for pol of HTLV-I) in 50% formamide, SX SSC, 0.02 mol/L sodium phosphate (pH 6.5), 1X Denhardt's solution, and 0.5 mg/mL of denatured salmon sperm DNA. Each filter was washed with 2X SSC-0.1% SDS and 0.1X SSC-0.1% SDS at 60°C and exposed to x-ray film.
Amplification of c-Ki-ras.
Southern blot analysis.

RESULTS
Detection of the HTLV-I genome by the PCR. When genomic DNA obtained from 134 HTLV-I carriers was amplified by 40 PCR cycles with primers forpol region and then analyzed by dot hybridization, 119 samples showed a positive reaction and 15 samples were negative. After Semiquantitative analysis of the HTLV-I genome dose.
Radioactivity of hybridized dot membranes was counted by the RI Imaging System. In each experiment, standard samples were also included to determine standard curves (a representative curve is shown in Fig 1) . ie, 0.001 to 100 copies of the HTLV-I genome per 100 cells). Positive dot hybridization was consistently obtained in samples with more than 0.1% HTLV-I genome positivity (equivalent to 0.1 copies of the genome per 100 cells). HTLV-I genome dose was determined using standard curves obtained from the serially diluted positive control samples, and the carriers' samples were classified into five groups depending on the genome dose. These groups were as follows: high, equivalent to more than 10 copies of the HTLV-I genome per 100 PBMC; moderately high, equivalent to 1 to 10 copies; and moderately low, equivalent to 0.1 to 1 copy. Samples that were estimated to contain less than 0.1 copy of the HTLV-I genome per 100 PBMC were classified as low. After 60 PCR cycles, standard samples containing 0.01 copy of the HTLV-I genome per 100 PBMC became consistently positive in dot hybridization, and those containing 0.001 copy were occasionally positive. Therefore, samples that were negative after 40 PCR cycles but
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All samples were examined at least three times. Whenever results were inconsistent, additional analyses were performed until repeatable results were obtained. To exclude the possibility that DNA preparations from particular samples could be inappropriate for the PCR, eg, due to contamination by enzyme inhibitors, each sample was also examined for c-Ki-ras gene expression. Consistent and uniform results were obtained for all samples, with a less than 20% standard deviation in cpm being detected (examples are shown in Fig 2) .
Analysis of the HTLV-I genome dose by the PCR for pol, pX, gag, and env regions. To determine the specificity of the PCR, 38 samples were analyzed in parallel forpol, pX, gag, and env regions of HTLV-I. Primers and detecting probes for each region are listed in Table 2 . Thirty-five samples showed essentially similar results by the PCR for all four regions in terms of HTLV-I genome dose. One sample determined as moderately high genome dose by the PCR forpol became moderately low genome dose when the three other regions were examined. The remaining two samples determined as high genome dose by the PCR for pol, gag, andpX became either moderately low or undetectable genome dose by the PCR for env region. An example of comparative analysis is shown in Fig 3. In addition, selected samples were also analyzed by the standard Southern blot analysis. As shown in an example (Fig 4) , expected bands were consistently detected by Southern blot analysis in samples with high genome dose and occasionally detected in samples with moderately high genome dose. Bands have never been detected in samples with lower genome doses.
In the PBMC of 134 asymptomatic HTLV-I carriers, we observed a wide range of variation of the integrated HTLV-I genome dose from more than 10 copies to less than 0.1 copy per 100 PBMC. Figure 5 shows the variations of HTLV-I genome dose with age in males and females. High genome dose was detected only in a limited number of carriers, who were predominantly males over 30 years old. Otherwise, no apparent differences in the proportion of carriers with different genome doses were observed among the various age groups.
HTLV-I genome dose in HTLV-I carriers.
DISCUSSION
The determination of host viral genome dose is extremely important for understanding the pathogenesis of virally related diseases, but reliable estimation of the viral dose is a matter of considerable technical difficulty. Thus, in the case of HTLV-I, the probable causative agent of ATL and several other disorders including HAM/TSP, only limited information on host genome levels has been available.
In this analysis we applied the PCR and the RI Imaging System to the determination of HTLV-I genome dose in viral carriers. Because HTLV-I is known to infect PBMC, particularly CD4' T cells, we analyzed PBMC genomic DNA. Thepol region was amplified by the PCR for detailed analysis of HTLV-I genome dose. Sufficient specificity and sensitivity were obtained for the PCR and dot hybridization by using predetermined HTLV-I' and HTLV-I-cells as controls and also by using the c-Ki-ras gene as an internal control. The semiquantitative results obtained from each sample based on standard curves for HTLV-I' genome DNA were also found to be specific and sufficiently repeatable. However, in several samples semiquantitative estimation by the RI Imaging System was not consistent in repeated experiments. Therefore, we had to repeat experiments for these samples four to five times before we obtained conclusive results. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
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were classified as having a moderately low or moderately high genome dose. Seventy-six percent (102 of 134) of the carriers had 0.1 to 10 HTLV-I genome copies in every 100 PBMC, while another 18% of the carriers (24 of 134) had less than 0.1 copy per 100 PBMC (low). Only seven carriers (5%) had more than 10 HTLV-I copies per 100 PBMC (high). Little age-related variation was observed in the proportion of individuals with low to moderately high HTLV-I genome dose. However, carriers with a high HTLV-I genome dose all were found to be more than 30 years old. This finding may suggest that the HTLV-I genome dose is largely determined shortly after viral transmission and does not change drastically afterwards, except in a rather limited number of individuals. Alternatively, a gradual increase of the HTLV-I genome dose after transmission may not have been detected in our study because of an increase of newly infected individuals among the older age groups. Sero-epidemiologic surveys in HTLV-I endemic areas have repeatedly shown that the rate of viral carriers, as determined by positivity for anti-HTLV-I antibody, apparently increases in parallel with aging.I9vm This increase could be at least partly explained by the possibility of antibody response to a latent virus infection acquired early in life, as proposed by Blattner et a1."
Yoshida et alZZ recently reported that integration of HTLV-I was detectable in 29% of asymptomatic carriers by the standard Southern blot analysis, whereas it was detected in 82% of patients with HAM/TSP. These results suggest that the levels of integrated HTLV-I genomes are higher in HAM/TSP patients than in asymptomatic carriers. Gessain et al' reported that 3% to 15% of the PBMC from HAM/TSP patients were infected by HTLV-I, after investigating 10 patients by dilution experiments using Southern blot hybridization assays. Although these analyses were performed in different populations and by different methods, it appears that HAM/TSP patients have a relatively high HTLV-I genome dose. In our preliminary analyses of 22 HAM/TSP patients, seven patients were determined as high genome dose, eight were moderately high genome dose, and the remaining seven were moderately low genome dose (data not shown). None were determined as low genome dose or undetectable genome dose. Our results are compatible with the previously mentioned reports and indicate an apparently higher level of HTLV-I genome dose in HAM/TSP patients. However, it has to be determined whether moderately high to high HTLV-I genome dose in asymptomatic virus carriers might be a risk factor for the development of HAM/TSP.
The presence of the abnormally shaped nucleus lymphoid cells is more frequent in carriers with high or moderately high HTLV-I genome dose than in those with lower genome dose (data not shown). Cytologic similarity between these cells and ATL cells suggests that they may be polyclonally proliferating HTLV-I-positive cells. These cells are also frequently found in peripheral blood samples of HAM/TSP patients. Therefore, it has to be determined if the appearance of these cells is directly relevant to the development of ATL and/or HAM/TSP.
